Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 117 stocks made new 52-week lows.
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
Expert Ratings For Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
SVB Leerink Maintains Outperform on Ascendis Pharma, Lowers Price Target to $178
SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $181 to $178.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
Monday morning, 285 companies reached new 52-week lows.
Ascendis Pharma Says Target Enrollment Achieved In Phase 3 PaTHway Trial Of TransCon
Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced it has reached the
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.
SVB Leerink Maintains Outperform on Ascendis Pharma, Lowers Price Target to $181
SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $191 to $181.
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $197
Morgan Stanley analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $201 to $197.